Muhammad Ali Memon

Muhammad Ali Memon

Auto-generated profile, based on publicly available information

Muhammad Ali Memon

AAVantgarde Bio srl, Milan, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2025 in Science Advances
Verified
Journal Article
Open access
RFRita Ferla
Rita Ferla
EPEugenio Pugni
Eugenio Pugni
MLMariangela Lupo
Mariangela Lupo
PTPaola Tiberi
Paola Tiberi
FFFederica Fioretto
Federica Fioretto
ITIvana Trapani
Ivana Trapani
Retinal gene therapy using dual adeno-associated viral (AAV) intein vectors can be applied to genetic forms of blindness caused by mutations in genes with coding sequences that exceed single AAV cargo capacity, such as Stargardt disease (STGD1), the most common inherited macular dystrophy. In view of clinical translation of dual AAV intein vectors, here we set to evaluate both the efficiency and safety of their subretinal administration in relevant large animal models. Accordingly, we have developed the first pig model of STGD1, which we found to accumulate lipofuscin similarly to patients. This accumulation is significantly reduced upon subretinal administration of dual AAV intein vectors whose safety and pharmacodynamics we then tested in nonhuman primates, which showed modest and reversible inflammation as well as high levels of photoreceptor transduction. This bodes well for further clinical translation of dual AAV intein vectors in patients with STGD1 as well as for other blinding diseases that require the delivery of large genes.

1 January 2022 in Computer Systems Science and Engineering
Verified
Journal Article
Open access
PDF file
MAMesfer Alrizq
Mesfer Alrizq
SSShauban Ali Solangi
Shauban Ali Solangi
AAAbdullah Alghamdi
Abdullah Alghamdi
MNMuhammad Ali Nizamani
Muhammad Ali Nizamani
MMMuhammad Ali Memon
Muhammad Ali Memon
MHMohammed Hamdi
Mohammed Hamdi
Recent advancements in the Internet of Things IoT and cloud computing have paved the way for mobile Healthcare (mHealthcare) services. A patient within the hospital is monitored by several devices. Moreover, upon leaving the hospital, the patient can be remotely monitored whether directly using body wearable sensors or using a smartphone equipped with sensors to monitor different user-health parameters. This raises potential challenges for intelligent monitoring of patient’s health. In this paper, an improved architecture for smart mHealthcare is proposed that is supported by HCI design principles. The HCI also provides the support for the User-Centric Design (UCD) for smart mHealthcare models. Furthermore, the HCI along with IoT`s (Internet of Things) 5-layered architecture has the potential of improving User Experience (UX) in mHealthcare design and help saving lives. The intelligent mHealthcare system is supported by the IoT sensing and communication layers and health care providers are supported by the application layer for the medical, behavioral, and health-related information. Health care providers and users are further supported by an intelligent layer performing critical situation assessment and performing a multi-modal communication using an intelligent assistant. The HCI design focuses on the ease-of-use, including user experience and safety, alarms, and error-resistant displays of the end-user, and improves user’s experience and user satisfaction.